NASDAQ:NDRA ENDRA Life Sciences Q1 2024 Earnings Report $5.98 -0.36 (-5.68%) Closing price 03:59 PM EasternExtended Trading$6.09 +0.11 (+1.84%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast ENDRA Life Sciences EPS ResultsActual EPS-$22,750.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AENDRA Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AENDRA Life Sciences Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call DateTuesday, May 14, 2024Conference Call Time4:30PM ETUpcoming EarningsENDRA Life Sciences' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by ENDRA Life Sciences Q1 2024 Earnings Call TranscriptProvided by QuartrMay 14, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:01Good day, and welcome to the ENDRA Life Sciences First Quarter 2024 Financial Results Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Speaker 100:00:40Thank you, operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to ENDRA Life Sciences' Q1 2024 business update and financial results conference call. Earlier today, ENDRA issued a press release on this topic, which is available in the Investors section of ENDRA's website. Before we begin, please note that today's discussion will include forward looking statements. Speaker 100:01:04All statements by management other than statements of historical facts are forward looking statements. These include statements regarding the company's strategies, financial condition, operations, costs, plans and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities and expectations regarding regulatory processes, receipt of required regulatory clearances and product launches. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward looking statements. Please refer to the company's Form 10 ks for the 2023 fiscal year and subsequent SEC filings for more information about risks and uncertainties related to forward looking statements. In terms of the structure of today's call, Francois Michelon, Chairman and Chief Executive Officer, will begin the prepared remarks, followed by Michael Thornton, ENDRA's Chief Technology Officer. Speaker 100:02:05Mr. Thornton will be followed by Irina Pestrykova, Senior Director of Finance, to review the Q1 financial results, and then we'll take your questions. I'll now turn the call over to Francois Michelon. Francois? Speaker 200:02:18Thank you, Yvonne, thanks for joining us today to review ENDRA's Q1 2024 financial results and key business developments. We're advancing on our mission to revolutionize metabolic health through the practical detection and monitoring of liver disease and we've made good progress in the following areas. First, activating new clinical research sites and target markets to build our body of clinical evidence at the local level across a range of sites, users and patient types. This clinical data is a foundational element to achieving commercial success in the future. 2nd, working closely with the FDA to align on clinical requirements for our TAEUS systems de novo application. Speaker 200:03:02A pre submission meeting is scheduled with the FDA in suburban Washington DC this quarter. 3rd, leveraging the accelerating market developments in the detection and treatment of liver disease to strengthen ENDRA's position. And 4th, looking beyond our current markets and technology to new opportunities to license our intellectual property. I'll elaborate on each of these elements. In the Q1, we achieved a milestone in one of our target markets by installing the first TAEUS system in the United Kingdom. Speaker 200:03:34King's College Hospital in London, a prestigious national health service institution is leading the introduction of ENDRA's liver system in the UK market. This partnership entails a clinical study comparing TAEUS's liver fat assessment accuracy versus MRI, the recognized research standard. The UK along with other active clinical study sites in the US are crucial for generating the body of clinical data needed to support the commercial adoption of our technology across radiology, hepatology and endocrinology in global markets. The clinical abstracts we presented last year at the European Association for the Study of the Liver were a great start, highlighting the impressive clinical performance of our technology compared to the MRI gold standard. But we need to continue to expand this pool of real world evidence demonstrate our clinical and economic value to potential users in our target markets at the local level. Speaker 200:04:36In addition to the foundational work of building our clinical evidence, ENDRA is working closely with the FDA to achieve alignment on clinical requirements for our TAEUS systems de novo application. ENDRA has had several interactions with the agency since Q4 of 2023 and we've provided additional information about our technology and historical clinical testing. To advance the review process and further align expectations with the aim of ultimately achieving a successful regulatory outcome, ENDRA has scheduled an in person pre submission meeting with the FDA this quarter focusing on clinical requirements. Mike will elaborate on this in a minute. On a broader market basis, key building blocks for diagnosing, treating and managing liver disease are rapidly advancing, providing hope for the millions who are affected and opportunities for companies like ENDRA. Speaker 200:05:32Leading clinical societies such as the American Diabetes Association and the American Association For Clinical Endocrinology have updated their guidelines and now recommend screening for fatty liver disease for pre diabetic, diabetic and obese patients. That's over 100,000,000 people in the U. S. Alone who need to be evaluated and MRI is not a practical solution for a population this large. A second building block relates to the FDA's recent approval of Resdiffra, Madrigal Pharmaceuticals pioneering drug therapy for NAFLD NASH, marking the beginning of a new chapter in liver disease management. Speaker 200:06:14This therapy along with other emerging targeted treatments for liver disease will significantly impact healthcare providers, insurers and patients. Major insurers like Blue Cross are requiring adherence to 9 specific prescribing authorization criteria for Resdiffra, including an MRI PDFF liver fat quantification exam, which can only be performed by the most advanced subset of the world's MRIs. This underscores the complexity of managing this disease and highlights the need for precision in diagnosis and treatment. Resdiffra and future drugs will consequently drive demand, we believe, for more accessible point of care diagnostic tools like ENDRIS TAEUS that are capable of facilitating the assessment and monitoring of liver disease affecting over 2,000,000,000 people globally. Finally, we're actively exploring collaborations and strategic pathways to expand the applications of our TAEUS platform beyond deliver. Speaker 200:07:18By leveraging our intellectual property and engaging in strategic partnerships and out licensing initiatives, we aim to capitalize on the potential of our TAEUS platform in new therapeutic areas. We've engaged Patentvest, a leading intellectual property advisory firm to spearhead ENDRA's IP valuation, competitive landscape analysis and licensing efforts. To that end, we're aggressively expanding our global intellectual property portfolio with the issuance of 8 new patents so far this year. With these additions, ENDRA's patent estate has reached an impressive 80 issued patents worldwide. These patents safeguard key innovations that are integral to the TAEUS system and reinforce our competitive edge in the marketplace. Speaker 200:08:07I'll now turn the call over to Mike Thornton for an overview of our clinical and regulatory advancements. Mike? Speaker 300:08:15Thanks, Francois. Today, I'll provide an update on regulatory developments for ENDRA's TAEUS system. ENDRA secured a valuable opportunity for an in person pre submission meeting in the Q2 with the FDA at their Maryland facility to prepare and submit a new de novo application. The focus of this meeting will be clinical trial design that is crucial for obtaining alignment with the FDA on our study design. We'll discuss key aspects, including the study design, study hypothesis and the statistical analysis plan. Speaker 300:08:50Further, we provided the FDA with a detailed description of the device and a master protocol that outlines the clinical study across multiple sites. This proposed study will cover a range of liver fat percentages, mirroring the prevalence of steatotic liver disease in the U. S. Population. ENDRA's pre submission team for the upcoming meeting includes key technical staff and an experienced regulatory lead with over 20 years of first of a kind medical device experience, a senior biostatistician that is familiar to the FDA and several radiology clinical experts. Speaker 300:09:27Why is ENDRA's approach different this time? Reflecting on our past regulatory strategies and the fast evolving medical imaging regulatory landscape, it's clear that ENDRA's historical reliance on clinical data derived from multiple feasibility studies was insufficient for FDA's current standards. The current approach is to work hand in hand with the FDA through its pre submission process to develop a prospective statistically powered pivotal trial, whose data will be acceptable to FDA for our de novo grants. We look forward to updating you on the outcomes of our FDA meeting and the next steps in our regulatory process. With that, I'll turn it over to Irina Pesrakova for our financial update. Speaker 300:10:10Irina? Speaker 400:10:12Thank you, Mike. Turning now to a review of our recent financial performance. For the quarter ended March 31, 2024, our operating expenses decreased to $2,800,000 from $2,900,000 for the same period in 2023. The decrease was mainly due to lower research and development expenses. Our research and development expenses decreased year over year by approximately $350,000 as we completed the development of our initial TAEUS product. Speaker 400:10:44Our sales and marketing expenses increased by approximately $57,000 mainly due to higher consulting fees. General and administrative expenses increased by approximately $134,000 mainly due to higher professional fees. Our net loss in the Q1 of 2024 was $2,800,000 or $0.26 per share. This compares with a net loss of $2,900,000 or $0.93 per share in the Q1 of 2023. Cash and cash equivalents were $1,100,000 as of March 31, 2024. Speaker 400:11:21In the first quarter, the company raised $420,000 in gross proceeds from the sale of common stock through at the market equity facility and $77,000 from the exercise of warrants. We're focused on managing our current resources and financing opportunities to maintain the capital necessary to progress our operating plan. Now, I'll turn the call back to Francois. Speaker 200:11:47Thanks, Irina and Mike. In summary, we remain committed to driving innovation and our market presence through the following four levers. Number 1, leveraging clinical partner sites in Europe and the U. S. To build our base of clinical evidence and achieve successful adoption of our technology. Speaker 200:12:06Number 2, engaging closely with the FDA to advance our regulatory submission in the US. Number 3, leveraging the accelerating market developments in the detection and treatment of liver disease to strengthen ENDRA's position. And 4th, leveraging our intellectual property to grow beyond our current markets and clinical focus. On behalf of the entire ENDRA team, once again, I extend my thanks to the shareholders for their continued support of ENDRA. And now operator, we're ready to open the call to questions. Operator00:12:57The first question comes from Edward Wu from Ascendiant Capital. Please go ahead. Speaker 500:13:02Hi, Ed. Yes. Thank you very much for the update. My question is on Asia. I know you have the distribution in Vietnam that will go live as soon as you get FDA approval. Speaker 500:13:14Is there any other parts of Asia that you're possibly thinking to go into? Speaker 200:13:19Thanks, Ed. Yeah, great question. I think, to put it in context before I get to any specifics on Asia, as a small company, we have to focus our resources. Obviously, we're starting strongly in Europe with the CE Mark. The UK clinical site is our anchor there. Speaker 200:13:35And as we've announced, we plan to carefully add more sites in our target markets, resources permitting. And then concurrently managed the FDA process and the 3 active sites we have in the U. S. On a pre FDA basis to prepare the U. S. Speaker 200:13:53Market. You're absolutely right. We've happy for that. That would go into effect upon FDA approval. And we also previously announced years ago or rather a couple of years ago the agreement we signed with Shanghai General Hospital as a clinical study site in the PRC. Speaker 200:14:23So we're definitely looking at Asia. We have a few anchor points through those two mechanisms. Asia obviously is a large market where liver disease is quite prevalent, But I would say that I'd like investors to hear, 1st and foremost, discipline and focus on being successful, 1st in Europe, then in the U. S. And leveraging then carefully with all that knowledge and the basic clinical evidence that I've mentioned, which would be foundational for it all to then go to Asia. Speaker 200:14:55So I hope that helps answer your question. Speaker 500:14:59Yes, it does. I wish you good luck with the FDA meeting and thank you and I wish you guys good luck. Thank you. Speaker 200:15:04Thank you so much, Ed. Operator, if we don't have any other questions, I think we can wrap up the call then. Operator00:15:12Thank you. This concludes the conference. Thank you for attending today's presentation. You may now disconnect. Speaker 200:15:21Thank you, everyone.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallENDRA Life Sciences Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ENDRA Life Sciences Earnings HeadlinesENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short InterestMay 3 at 3:39 AM | americanbankingnews.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secret. Now, leaked computer code confirms Elon is moments away from launching a revolutionary financial technology… And Silicon Valley insider Jeff Brown says it could hand early investors who missed Tesla, "the ultimate second chance" to get rich.May 6, 2025 | Brownstone Research (Ad)ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 TherapiesMarch 31, 2025 | businesswire.comENDRA Life Sciences Inc Registered Shs NDRAFebruary 2, 2025 | morningstar.comENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementNovember 22, 2024 | businesswire.comSee More ENDRA Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email. Email Address About ENDRA Life SciencesENDRA Life Sciences (NASDAQ:NDRA) develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.View ENDRA Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Upcoming Earnings ARM (5/7/2025)AppLovin (5/7/2025)Fortinet (5/7/2025)MercadoLibre (5/7/2025)Cencora (5/7/2025)Carvana (5/7/2025)Walt Disney (5/7/2025)Emerson Electric (5/7/2025)Johnson Controls International (5/7/2025)Lloyds Banking Group (5/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:01Good day, and welcome to the ENDRA Life Sciences First Quarter 2024 Financial Results Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Yvonne Briggs. Please go ahead. Speaker 100:00:40Thank you, operator. This is Yvonne Briggs with LHA. Good afternoon and welcome to ENDRA Life Sciences' Q1 2024 business update and financial results conference call. Earlier today, ENDRA issued a press release on this topic, which is available in the Investors section of ENDRA's website. Before we begin, please note that today's discussion will include forward looking statements. Speaker 100:01:04All statements by management other than statements of historical facts are forward looking statements. These include statements regarding the company's strategies, financial condition, operations, costs, plans and objectives, as well as anticipated results of development and commercialization efforts, the timing of clinical studies, potential partnership opportunities and expectations regarding regulatory processes, receipt of required regulatory clearances and product launches. Except as required by federal securities laws, the company disclaims any obligation to update or revise any forward looking statements. Please refer to the company's Form 10 ks for the 2023 fiscal year and subsequent SEC filings for more information about risks and uncertainties related to forward looking statements. In terms of the structure of today's call, Francois Michelon, Chairman and Chief Executive Officer, will begin the prepared remarks, followed by Michael Thornton, ENDRA's Chief Technology Officer. Speaker 100:02:05Mr. Thornton will be followed by Irina Pestrykova, Senior Director of Finance, to review the Q1 financial results, and then we'll take your questions. I'll now turn the call over to Francois Michelon. Francois? Speaker 200:02:18Thank you, Yvonne, thanks for joining us today to review ENDRA's Q1 2024 financial results and key business developments. We're advancing on our mission to revolutionize metabolic health through the practical detection and monitoring of liver disease and we've made good progress in the following areas. First, activating new clinical research sites and target markets to build our body of clinical evidence at the local level across a range of sites, users and patient types. This clinical data is a foundational element to achieving commercial success in the future. 2nd, working closely with the FDA to align on clinical requirements for our TAEUS systems de novo application. Speaker 200:03:02A pre submission meeting is scheduled with the FDA in suburban Washington DC this quarter. 3rd, leveraging the accelerating market developments in the detection and treatment of liver disease to strengthen ENDRA's position. And 4th, looking beyond our current markets and technology to new opportunities to license our intellectual property. I'll elaborate on each of these elements. In the Q1, we achieved a milestone in one of our target markets by installing the first TAEUS system in the United Kingdom. Speaker 200:03:34King's College Hospital in London, a prestigious national health service institution is leading the introduction of ENDRA's liver system in the UK market. This partnership entails a clinical study comparing TAEUS's liver fat assessment accuracy versus MRI, the recognized research standard. The UK along with other active clinical study sites in the US are crucial for generating the body of clinical data needed to support the commercial adoption of our technology across radiology, hepatology and endocrinology in global markets. The clinical abstracts we presented last year at the European Association for the Study of the Liver were a great start, highlighting the impressive clinical performance of our technology compared to the MRI gold standard. But we need to continue to expand this pool of real world evidence demonstrate our clinical and economic value to potential users in our target markets at the local level. Speaker 200:04:36In addition to the foundational work of building our clinical evidence, ENDRA is working closely with the FDA to achieve alignment on clinical requirements for our TAEUS systems de novo application. ENDRA has had several interactions with the agency since Q4 of 2023 and we've provided additional information about our technology and historical clinical testing. To advance the review process and further align expectations with the aim of ultimately achieving a successful regulatory outcome, ENDRA has scheduled an in person pre submission meeting with the FDA this quarter focusing on clinical requirements. Mike will elaborate on this in a minute. On a broader market basis, key building blocks for diagnosing, treating and managing liver disease are rapidly advancing, providing hope for the millions who are affected and opportunities for companies like ENDRA. Speaker 200:05:32Leading clinical societies such as the American Diabetes Association and the American Association For Clinical Endocrinology have updated their guidelines and now recommend screening for fatty liver disease for pre diabetic, diabetic and obese patients. That's over 100,000,000 people in the U. S. Alone who need to be evaluated and MRI is not a practical solution for a population this large. A second building block relates to the FDA's recent approval of Resdiffra, Madrigal Pharmaceuticals pioneering drug therapy for NAFLD NASH, marking the beginning of a new chapter in liver disease management. Speaker 200:06:14This therapy along with other emerging targeted treatments for liver disease will significantly impact healthcare providers, insurers and patients. Major insurers like Blue Cross are requiring adherence to 9 specific prescribing authorization criteria for Resdiffra, including an MRI PDFF liver fat quantification exam, which can only be performed by the most advanced subset of the world's MRIs. This underscores the complexity of managing this disease and highlights the need for precision in diagnosis and treatment. Resdiffra and future drugs will consequently drive demand, we believe, for more accessible point of care diagnostic tools like ENDRIS TAEUS that are capable of facilitating the assessment and monitoring of liver disease affecting over 2,000,000,000 people globally. Finally, we're actively exploring collaborations and strategic pathways to expand the applications of our TAEUS platform beyond deliver. Speaker 200:07:18By leveraging our intellectual property and engaging in strategic partnerships and out licensing initiatives, we aim to capitalize on the potential of our TAEUS platform in new therapeutic areas. We've engaged Patentvest, a leading intellectual property advisory firm to spearhead ENDRA's IP valuation, competitive landscape analysis and licensing efforts. To that end, we're aggressively expanding our global intellectual property portfolio with the issuance of 8 new patents so far this year. With these additions, ENDRA's patent estate has reached an impressive 80 issued patents worldwide. These patents safeguard key innovations that are integral to the TAEUS system and reinforce our competitive edge in the marketplace. Speaker 200:08:07I'll now turn the call over to Mike Thornton for an overview of our clinical and regulatory advancements. Mike? Speaker 300:08:15Thanks, Francois. Today, I'll provide an update on regulatory developments for ENDRA's TAEUS system. ENDRA secured a valuable opportunity for an in person pre submission meeting in the Q2 with the FDA at their Maryland facility to prepare and submit a new de novo application. The focus of this meeting will be clinical trial design that is crucial for obtaining alignment with the FDA on our study design. We'll discuss key aspects, including the study design, study hypothesis and the statistical analysis plan. Speaker 300:08:50Further, we provided the FDA with a detailed description of the device and a master protocol that outlines the clinical study across multiple sites. This proposed study will cover a range of liver fat percentages, mirroring the prevalence of steatotic liver disease in the U. S. Population. ENDRA's pre submission team for the upcoming meeting includes key technical staff and an experienced regulatory lead with over 20 years of first of a kind medical device experience, a senior biostatistician that is familiar to the FDA and several radiology clinical experts. Speaker 300:09:27Why is ENDRA's approach different this time? Reflecting on our past regulatory strategies and the fast evolving medical imaging regulatory landscape, it's clear that ENDRA's historical reliance on clinical data derived from multiple feasibility studies was insufficient for FDA's current standards. The current approach is to work hand in hand with the FDA through its pre submission process to develop a prospective statistically powered pivotal trial, whose data will be acceptable to FDA for our de novo grants. We look forward to updating you on the outcomes of our FDA meeting and the next steps in our regulatory process. With that, I'll turn it over to Irina Pesrakova for our financial update. Speaker 300:10:10Irina? Speaker 400:10:12Thank you, Mike. Turning now to a review of our recent financial performance. For the quarter ended March 31, 2024, our operating expenses decreased to $2,800,000 from $2,900,000 for the same period in 2023. The decrease was mainly due to lower research and development expenses. Our research and development expenses decreased year over year by approximately $350,000 as we completed the development of our initial TAEUS product. Speaker 400:10:44Our sales and marketing expenses increased by approximately $57,000 mainly due to higher consulting fees. General and administrative expenses increased by approximately $134,000 mainly due to higher professional fees. Our net loss in the Q1 of 2024 was $2,800,000 or $0.26 per share. This compares with a net loss of $2,900,000 or $0.93 per share in the Q1 of 2023. Cash and cash equivalents were $1,100,000 as of March 31, 2024. Speaker 400:11:21In the first quarter, the company raised $420,000 in gross proceeds from the sale of common stock through at the market equity facility and $77,000 from the exercise of warrants. We're focused on managing our current resources and financing opportunities to maintain the capital necessary to progress our operating plan. Now, I'll turn the call back to Francois. Speaker 200:11:47Thanks, Irina and Mike. In summary, we remain committed to driving innovation and our market presence through the following four levers. Number 1, leveraging clinical partner sites in Europe and the U. S. To build our base of clinical evidence and achieve successful adoption of our technology. Speaker 200:12:06Number 2, engaging closely with the FDA to advance our regulatory submission in the US. Number 3, leveraging the accelerating market developments in the detection and treatment of liver disease to strengthen ENDRA's position. And 4th, leveraging our intellectual property to grow beyond our current markets and clinical focus. On behalf of the entire ENDRA team, once again, I extend my thanks to the shareholders for their continued support of ENDRA. And now operator, we're ready to open the call to questions. Operator00:12:57The first question comes from Edward Wu from Ascendiant Capital. Please go ahead. Speaker 500:13:02Hi, Ed. Yes. Thank you very much for the update. My question is on Asia. I know you have the distribution in Vietnam that will go live as soon as you get FDA approval. Speaker 500:13:14Is there any other parts of Asia that you're possibly thinking to go into? Speaker 200:13:19Thanks, Ed. Yeah, great question. I think, to put it in context before I get to any specifics on Asia, as a small company, we have to focus our resources. Obviously, we're starting strongly in Europe with the CE Mark. The UK clinical site is our anchor there. Speaker 200:13:35And as we've announced, we plan to carefully add more sites in our target markets, resources permitting. And then concurrently managed the FDA process and the 3 active sites we have in the U. S. On a pre FDA basis to prepare the U. S. Speaker 200:13:53Market. You're absolutely right. We've happy for that. That would go into effect upon FDA approval. And we also previously announced years ago or rather a couple of years ago the agreement we signed with Shanghai General Hospital as a clinical study site in the PRC. Speaker 200:14:23So we're definitely looking at Asia. We have a few anchor points through those two mechanisms. Asia obviously is a large market where liver disease is quite prevalent, But I would say that I'd like investors to hear, 1st and foremost, discipline and focus on being successful, 1st in Europe, then in the U. S. And leveraging then carefully with all that knowledge and the basic clinical evidence that I've mentioned, which would be foundational for it all to then go to Asia. Speaker 200:14:55So I hope that helps answer your question. Speaker 500:14:59Yes, it does. I wish you good luck with the FDA meeting and thank you and I wish you guys good luck. Thank you. Speaker 200:15:04Thank you so much, Ed. Operator, if we don't have any other questions, I think we can wrap up the call then. Operator00:15:12Thank you. This concludes the conference. Thank you for attending today's presentation. You may now disconnect. Speaker 200:15:21Thank you, everyone.Read morePowered by